Edwards Announces FDA Approval For KONECT RESILIA Aortic Valved Conduit - Quick Facts

(RTTNews) - Edwards Lifesciences Corp. (EW) has received approval from the U.S. FDA for the KONECT RESILIA aortic valved conduit, the first ready-to-implant solution for bio-Bentall procedures. The KONECT device comes with the advanced RESILIA tissue, which incorporates integrity-preservation technology that may help improve valve durability.

Daveen Chopra, Edwards' corporate vice president, surgical structural heart, said: "Because the typical patient is under the age of 60, advanced technologies such as the KONECT device with the RESILIA tissue might provide extended valve durability for a more active patient population."

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More